title: Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
abstract: OBJECTIVE
  Short, intensive multiagent chemotherapy has resulted in significant progress in Burkitt's lymphoma and leukemia. A protocol was designed to treat all adult patients with mature B-cell lymphoma or leukemia with the aims of comparing the response to therapy and survival with regards to their HIV infection status.
  
  
  METHODS
  Fifty-three adult patients with advanced stage Burkitt's lymphoma or Burkitt's leukemia were treated. Response to therapy, survival and toxicity were evaluated according to their HIV infection status.
  
  
  RESULTS
  The median age of the patients was 53 years (range 15-74). There were no differences in CR rates between HIV-negative (77%) and HIV-positive patients (71%). Only age > 60 years was associated with a lower CR rate (OR 0.18, 95%CI 0.04-0.81, p=0.026). The 2-year overall survival (OS) probability was 51% (95%CI, 38%-64%) for the 53 patients. The OS of HIV-negative and HIV-positive patients did not significantly differ. Only age > 60 years was associated with a shorter OS (OR 5.1, 95%CI 2.0-12.7, p=0.001). The 2-year disease free survival (DFS) for the 40 patients achieving CR was 60% (95%CI, 45%-75%). Age > 60 years was the only identified factor associated with a shorter DFS (OR 5.2, 95%CI 1.4-20, p=0.015).
  
  
  CONCLUSIONS
  This study confirms the effectiveness of intensive strategies in adult patients with advanced stage Burkitt's lymphoma or leukemia. It also shows the feasibility of these strategies in individuals with HIV infection with comparable results. Advanced age proved to be the main adverse prognostic factor for response to therapy and survival.
authors.affiliation: Servei d'Hematologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Ribera
authors.forename: Jordi
authors.initials: J
authors.lastname: Esteve
authors.forename: Miguel-Angel
authors.initials: MA
authors.lastname: Sanz
authors.forename: Salut
authors.initials: S
authors.lastname: Brunet
authors.forename: Raimundo
authors.initials: R
authors.lastname: Garcia-Boyero
authors.forename: Pascual
authors.initials: P
authors.lastname: Fernández-Abellán
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Martí
authors.forename: Eugènia
authors.initials: E
authors.lastname: Abella
authors.forename: Magdalena
authors.initials: M
authors.lastname: Sánchez-Delgado
authors.forename: Maria-Jesús
authors.initials: MJ
authors.lastname: Peñarrubia
authors.forename: Joan
authors.initials: J
authors.lastname: Besalduch
authors.forename: Maria-José
authors.initials: MJ
authors.lastname: Moreno
authors.forename: Domingo
authors.initials: D
authors.lastname: Borrego
authors.forename: Evarist
authors.initials: E
authors.lastname: Feliu
authors.forename: Juan-José
authors.initials: JJ
authors.lastname: Ortega
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity; D002051:Burkitt Lymphoma / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D015658:HIV Infections / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome